ArticleDiscover oncology2025
PXMP2 inhibits tumor stemness and immune infiltration in hepatocellular carcinoma based on stemness risk.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) is a complex and heterogeneous disease wherein cancer stem cells (CSCs) play a pivotal role in driving tumorigenesis, metastasis, and resistance to therapy. This study sought to map the stemness landscape of HCC and identify patients who may benefit from immunotherapy.
methodsA total of 26 stem cell gene sets were obtained from the StemChecker database. A stemness risk model was constructed based on data from TCGA, GEO databases, and bioinformatics methods. The hub genes identified in the model underwent significant preliminary in vitro and in vivo phenotypic validation, which included evaluating their effects on tumor stemness and their functional roles and interactions in TME. This basic verification emphasized the clinical relevance of hub genes and confirmed the practicality of the model in HCC stemness risk assessment and immune infiltration risk assessment, thereby providing a basis for potential treatment strategies.
resultsHCC patients exhibited three subtypes; C1 showed the worst prognosis, which was linked to high stemness risk and immunosuppressive features. The hub gene PXMP2 demonstrated tumor-suppressive properties by inhibiting tumor stemness in both in vitro and in vivo experiments, promoting the infiltration of anti-tumor M1 macrophages while simultaneously suppressing the infiltration of immunosuppressive M2 macrophages and neutrophils. Moreover, the high expression of PXMP2 was correlated with a favorable prognosis for the patients.
conclusionsThis study identified three distinct stemness-based subtypes of HCC and established a novel three-gene prognostic risk model. Our findings highlight the critical role of PXMP2 in tumor biology and its potential as a therapeutic target, paving the way for personalized immunotherapy and chemotherapy approaches to enhance clinical outcomes in HCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.